Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News enVVeno Medical Corp NVNO

Healthcare Medical Devices
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system... see more

Recent & Breaking News (NDAQ:NVNO)

Hancock Jaffe Laboratories Announces Pricing of Upsized $36 Million Offering

Accesswire February 9, 2021

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Accesswire January 12, 2021

Hancock Jaffe Announces Executive Promotions

Accesswire December 30, 2020

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Accesswire December 21, 2020

Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone

Accesswire December 16, 2020

Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data

Accesswire December 15, 2020

Hancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve Patient

Accesswire December 14, 2020

Hancock Jaffe to Provide VenoValve and CoreoGraft Updates at Ladenburg Thalmann R&D Showcase Webinar on December 16, 2020

Accesswire December 10, 2020

Hancock Jaffe Announces One Year Follow-up Data on Tenth VenoValve Patient

Accesswire December 1, 2020

Hancock Jaffe Announces Reverse Stock Split

Accesswire November 27, 2020

Hancock Jaffe's VenoValve(R) Results Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders

Accesswire November 23, 2020

Hancock Jaffe Announces Date for VenoValve Pre-IDE Meeting with FDA

Accesswire November 5, 2020

Hancock Jaffe Reports Successful Completion of First CoreoGraft Heart Bypass Surgery

Accesswire October 28, 2020

Hancock Jaffe Submits VenoValve Pre-IDE Filing to FDA

Accesswire October 27, 2020

Hancock Jaffe Announces One Year Follow-up Data on Ninth VenoValve Patient

Accesswire October 21, 2020

Hancock Jaffe to Begin CoreoGraft First-in-Human Study

Accesswire October 14, 2020

Hancock Jaffe Engages Syntactx for VenoValve U.S. Pivotal Trial

Accesswire October 8, 2020

Hancock Jaffe Laboratories, Inc. Announces Pricing of $5.1 Million Registered Direct Offering Priced at the Market

Accesswire October 7, 2020

Hancock Jaffe Announces Positive Nasdaq Listing Determination

Accesswire September 21, 2020

Hancock Jaffe Enrolls Initial Patients for First-in-Human CoreoGraft Study

Accesswire August 25, 2020